— McKesson Corporation (NYSE: MCK) reported third-quarter 2019 earnings of $3.60 per share, in line with the street projection.
— Total revenue grew 9% to $57.62 billion, vs $55.07 billion expected. The topline was driven by its US Pharmaceutical and Specialty Solutions segment.
— Revenues from US Pharma segment were $46.0 billion, up 10%, driven by branded pharmaceutical price increases and increased specialty pharmaceutical volumes.
— Reaffirms fiscal 2020 adjusted EPS guidance range of $14.00 – $14.60.
— CME shares have gained 0.7% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
